Unicycive is focused on delivering disease-modifying therapies for major global health issues, particularly in relation to kidney diseases.

Unicycive

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

COM:UNICYCIVE

Unicycive

Last Close

0.44

25/09 14:39

Market Cap

41.21M

Beta: -

Volume Today

350.39K

Avg: -

Filings Not Available